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The proper algorithm for the radiographic evaluation of children with febrile urinary tract infection (FUTI) is hotly debated.
Three studies are commonly administered: renal-bladder ultrasound (RUS), voiding cystourethrogram (VCUG), and dimercapto-
succinicacid(DMSA)scan.However,theorderinwhichthesetestsareobtaineddependsonthemethodologyfollowed:bottom-up
or top-down. Each strategy carries advantages and disadvantages, and some groups now advocate even less of a workup (none of
the above) due to the current controversies about treatment when abnormalities are diagnosed. New technology is available and
still under investigation, but it may help to clarify the interplay between vesicoureteral reﬂux, renal scarring, and dysfunctional
elimination in the future.
1.Introduction
Three studies are commonly employed in the workup of
febrile urinary tract infections (FUTIs): renal-bladder ultra-
sound (RUS), voiding cystourethrogram (VCUG), and di-
mercaptosuccinic acid (DMSA) scan. This paper will discuss
the rationale behind the timing of these studies (“top-down”
versus“bottom-up”methodology),alongwiththeindividual
advantages and limitations of each approach. The debate
involves the ideal outcome of interest vesicoureteral reﬂux
(bottom-up) or renal parenchymal involvement (top-down).
The controversy on this topic has swelled to the point that
certain forums are even promoting a more limited workup
(none of the above) for a subset of patients. Finally, new
techniquesandtechnologiesusingmagneticresonance(MR)
urography and voiding urosonography (VUS) are emerging.
These innovative studies may impact management strategies
in the future. The purpose of this paper is to assess the
current literature on bottom-up and top-down approaches
as well as newer modalities and to evaluate the association
between vesicoureteral reﬂux and renal scarring as it pertains
to the workup of a child with FUTI.
2.Background
Urinary tract infections (UTIs) in young children are com-
mon with an overall prevalence of 7.0% among infants
presentingwithfeverandapooledprevalenceof7.8%among
children with urinary symptoms [1]. This diagnosis often
leads to a radiographic workup to look for correctable uri-
nary tract abnormalities that may predispose the child to
infection. The objective is to identify which patients are sus-
ceptible to renal damage. Ideally, medical or surgical inter-
ventions can then be employed to prevent this cohort from
developing future infections or sustaining further injury
(although this point is also controversial). Scarring from
repeated infections of the renal parenchyma leads to hyper-
tensionin10to20%ofpatients[2].Also,reﬂuxnephropathy
progresses to end-stage renal disease requiring dialysis or
transplantation in 10 to 25% of patients worldwide [2–5].
Thus, the radiographic workup is critical in determining ap-
propriate therapy, but there is little agreement as to whether
the emphasis should be on the appearance of the kidneys
versus the presence of VUR.
Historically, the studies most commonly used for this
purpose were a RUS and VCUG. Collectively, this is now2 Advances in Urology
referred to as the “bottom-up” approach. This method relies
on renal-bladder ultrasound (RUS) to identify anatomic ir-
regularities (renal parenchymal defects) or evidence of ob-
struction. The voiding cystourethrogram (VCUG) targets
lower urinary tract abnormalities and detects vesicoureteral
reﬂux(VUR).Patientsdiagnosedwithreﬂuxorparenchymal
deformity may undergo a DMSA scan at a later date to assess
for scarring (Figure 1). Alternatively, the “top-down” ap-
proach targets the kidney at the outset with a DMSA scan
to diagnose acute renal parenchymal involvement at the time
of the FUTI. Patients that have photon defects or evidence
of parenchymal inﬂammation are subsequently referred for a
VCUG to assess for reﬂux in addition to a late DMSA (6–12
months) to assess for permanent scarring [6].
Although it seems to be a minor point, the critical issue
is the order in which these tests are performed. With either
method, a negative study will obviate the need for further
investigation. For the bottom-up approach, fewer DMSA
scans will be performed. The same will be true for VCUG
studies in the top-down approach. Why do two distinct
methodologies exist? In brief, the VCUG is a stressful study
for the patient and family due to the need for catheterization
[7, 8]. In addition, it identiﬁes a population with VUR that
may never be clinically signiﬁcant. Thus, the top-down ap-
proach has been advocated in some circles because a negative
DMSA precludes the need for a catheter and a positive study
identiﬁes the cohort that is most “at-risk” for subsequent
renal scarring. However, each approach has merits and ﬂaws;
these points will be reviewed below.
3.RadiographicOptions
3.1. Bottom-Up Approach. Voiding cystourethrogram
(VCUG) is the gold-standard exam to assess for vesicour-
eteral reﬂux (VUR). However, only 30–40% of children with
a UTI will have reﬂux, which suggests that over 60% of
VCUG tests ordered for this indication may be unnecessary
[9, 10]. The 1999 American Academy of Pediatrics (AAP)
practice guidelines recommend the regimen we now recog-
nize as the “bottom-up” approach to FUTI based on the
association between UTIs and urinary tract abnormalities
[11]. At the time, it was thought that VUR was necessary for
renal scarring to occur, so the presence of reﬂux was used
a surrogate for the true endpoint of interest: renal paren-
chymal injury.
Now it is recognized that the actual relationship between
VUR and renal scarring is poorly understood. In other
words, one does not have to have reﬂux to develop a scar,
and one does not always develop scarring with a reﬂux-
associated UTI. However, numerous studies continue to
support an association between reﬂux and scarring. A recent
prospective study of 227 children hospitalized with their
ﬁrst FUTI found that VUR continues to be a signiﬁcant
predictive factor for acute pyelonephritis (APN) featuring
renal parenchymal involvement and ultimate injury [12].
MorepatientswithVURpresentedwithacutephotondefects
on initial DMSA scan (P = 0.034) and progressed to scar
formation (P = 0.004). Surprisingly, even though there
was an association between VUR grade and acute photon
defects (P = 0.001), there was no correlation between VUR
grade and subsequent scar formation (P = 0.279). A recent
systematic review of the published literature revealed that
children with VUR were signiﬁcantly more likely to have
APN and renal scarring versus those without VUR (RR 1.5
and 2.6, resp.) [13]. In this paper, scarring was more likely
with grade III or greater VUR (RR 2.1). Furthermore, there
are higher rates of febrile infections in children with VUR
andUTI[9].Insummary,therelationshipbetweenVURand
renal scarring is clearly not 1:1; however, some association
undeniably exists, and this forms the basis for the VCUG
recommendation to identify those individuals with reﬂux
that may be at subsequent risk for secondary scarring.
The bottom-up tactic will readily identify reﬂux, but it
is diﬃcult to predict which subset of patients will spontane-
ously resolve and which will have harmful sequela of their
disease.Thus,aproportionofpatientswithreﬂuxwillunder-
go the morbidity of surveillance and potentially be subjected
to overtreatment. A recent prospective observational study
followed 115 infants diagnosed with high grade (III to V)
VUR [14]. Spontaneous complete resolution of VUR was
reportedin30patients(26%).Another14(12%)weredown-
graded to grade I to II reﬂux for an overall resolution rate
of 38%. The median age at which resolution occurred was
27 months [14]. As mentioned above, VUR does not always
lead to scarring in the setting of a FUTI [2, 15, 16]. Similarly,
although VUR has been associated with renal injury, there
is a 30% chance in children <1 year and 37% chance in
those aged 1–5 years that scarring may exist in the absence
of this abnormality [16, 17]. These ﬁndings indicate that the
VCUG will only partially identify the population that is at-
risk (because VUR may spontaneously resolve and not all
VUR + UTI = scar) and it will miss a subset of children that
experience renal scarring without VUR.
The other component of the bottom-up approach is
RUS; although, it would not be uncommon to see this study
ordered in conjunction with the top-down approach as well.
Ultrasound is the most common initial intervention for
a child with febrile or afebrile UTI. It provides a gross
anatomic assessment of the urinary tract that is noninvasive
and does not use ionizing radiation. However, given the cur-
rent frequency of prenatal ultrasounds, most children with
congenital obstruction of the urinary tract are diagnosed
before birth and treated before the ﬁrst UTI occurs [8, 18].
This suggests that an infant with uncomplicated FUTI does
not need a RUS if a reliable assessment was performed in
the third trimester. Ultrasound is an integral part of most
urologic workups and surveillance such that it is often a
knee-jerk reaction to order one upon referral; however, the
added beneﬁt that this study contributes for an infant with
FUTI is negligible in the era of prenatal screening.
Several studies have found that ultrasound fails to alter
management over DMSA scanning or VCUG [18]. Mahant
et al. [19] observed that RUS only carries a sensitivity and
speciﬁcity of 40% and 76%, respectively, for VUR. Certainly
the VCUG and DMSA scan in combination are capable of
diagnosing a wide range of genitourinary anomalies includ-
ingVUR,posteriorurethralvalves,duplexsystems,moderate
to severe hydronephrosis, and anatomic or function renalAdvances in Urology 3
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Figure 1: A schematic of the bottom-up versus top-down approach.
asymmetry [20]. Although it is widely available, the quality
of the study is technician dependent, it does not provide
a quantitative assessment of renal function, and it is not
sensitive enough to detect all scarring. On the other hand, it
is often comforting to the family to have a safe, noninvasive
exam that grossly reveals the condition of the kidneys. While
there may not be suﬃcient evidence to say that RUS is
absolutely necessary to the workup, it is very reasonable to
include it.
3.2. Top-Down Approach. DMSA has replaced the intrave-
nous urogram as the gold-standard study to assess for acute
renal inﬂammation and established parenchymal injury
(scarring). One basic tenet of the top-down approach is that
an early DMSA renal scan (in the acute phase of the febrile
illness) can detect renal involvement that signiﬁes the kidney
is vulnerable to subsequent injury. Thus, one only obtains a
VCUG in those patients that have evidence of a parenchymal
defect on a DMSA renal scan. This will theoretically identify
a more vulnerable population with reﬂux, one that has pa-
renchymal involvement with a FUTI, and lessen the need for
VCUGs in all patients with FUTI. This viewpoint recognizes
renal parenchymal infection, rather than VUR, as the nidus
for acquired scarring [15, 21, 22]. Serial DMSA scans show
that if new scars develop, they are localized to previous sites
of inﬂammation.
Itbearsmentioningthatthereisalackofconsensusabout
the etiology and signiﬁcance of scars seen on initial DMSA
or RUS. It has been argued that congenital dysplasia may
account for these defects rather than an acute insult to the
renal parenchyma from infection and/or reﬂux because
infantswithantenatalhydronephrosisthatneverexperienced
aU T Ic a nh a v ea na b n o r m a lD M S As t u d y[ 21, 23]. Part of
this argument considers scarring and VUR to be a global
development problem where the entire unit from kidney
to ureter is abnormal through embryologic development as
opposed to an evolving, acquired event after birth [23, 24].
As with the bottom-up approach, the concern is that an
abnormal DMSA scan will mistakenly identify children with
congenital dysplasia as part of the population susceptible to
further injury when, in fact, their lesions are static. Nev-
ertheless, acute pyelonephritis (APN) leads to detectable in-
ﬂammation on acute DMSA imaging and will cause sub-
sequent scarring in at least 50% of patients [24, 25]. In either
scenario, a subset of children will potentially be subjected to
over-treatment. However, the morbidity of surveillance in a
child with clinically insigniﬁcant reﬂux is arguably greater
than the conservative management of a child with a congen-
itally dysplastic kidney.
A common criticism of the top-down approach is that it
will miss VUR that does not have renal involvement. How-
ever, the majority of missed cases tend to be low-grade or
grade III VUR that resolves or improves on followup and
is not clinically signiﬁcant (deﬁned as dilating grade III-
IV VUR, or VUR associated with recurrent UTI, scarring,
or signiﬁcant dysfunctional elimination) [2, 21]. A recent
prospective trial of 121 children presenting with a ﬁrst FUTI
showed APN on 88 (73%) of acute phase (less than 7 days
after fever or symptom onset) DMSA studies [2]. VUR was
present in 78 patients (64%). The abnormal acute DMSA
predicted clinically signiﬁcant VUR with an odds ratio of
35.4. These children were followed for 5 years with repeat
DMSA performed at 6 months. 26 (21.5%) of the 88 initially
abnormal studies showed subsequent renal scarring. Of this
latter group, 14 had VUR and 12 did not. The initial DMSA
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and the top-down approach would have avoided 42 (35%)
VCUGs in patients who did not develop scarring [2].
Moorthy et al. [26] reviewed the records of 108 children
presenting with a ﬁrst UTI under the age of 1 year. Of 216
renal units (RU) that were normal on RUS, 8 had scarring on
DMSA 3–6 months after presentation. Although VUR was
demonstrated in 25RU, only 4 had concomitant scarring.
In summary, these studies reinforce the notion that renal
involvement and scarring can exist in the presence and
absence of VUR. Thus, the VCUG can safely be an adjunct
study to the principal DMSA exam to better identify an at
risk cohort. The DMSA deﬁnes the susceptible population,
and the VCUG identiﬁes the proportion that may be at risk
for further parenchymal damage and should be considered
for antibiotic prophylaxis and/or surgical intervention.
T h ea c u t ep h a s eD M S Ai sac r i t i c a lc o m p o n e n to ft h e
top-down approach as late phase exams may miss children
who present with repeat FUTI that does not result in scar-
ring [15, 24]. In the previously cited study, the sensitivity
and speciﬁcity for acute phase DMSA to detect clinically
signiﬁcant VUR were 95.7% and 71.9%, respectively [2].
Late phase DMSA scans had a sensitivity and speciﬁcity of
27.5% and 76.9%, respectively, for the same population. The
natural history of DMSA defects was studied prospectively to
assess the impact of scars on renal growth [26]. 50 children
with scarring on DMSA scan 6 months after an episode of
APN demonstrated improvement in 72% of lesions over a
3-year period, regardless of VUR status. Although a higher
number of scars was associated with higher grades of VUR
(P = 0.02), the number of scars observed at 6 months, and
not the severity of VUR, was associated with impaired renal
growth (P<0.001,P = 0.34, resp.). Although some kidneys
are vulnerable to injury, this study suggests that not all
defectsseenat6monthsareclinicallysigniﬁcantbecausethey
improve over time [26]. In summary, the appearance of
the kidneys on DMSA can evolve. Thus, obtaining a study
during the initial episode of FUTI is critical to identifying
the population with kidneys susceptible to injury and repeat
febrile infection, even though this may not result in a deﬁn-
itive scar.
Exposure to ionizing radiation remains as a common
criticism for both VCUG and DMSA studies. It has been
argued that, historically, VCUG transmits a larger dose of
radiation to the pediatric gonads in comparison to DMSA
[20].However,DMSAcarriesa10-foldhigherradiation dose
than pulsed ﬂuoroscopy, which is currently used in most
centers for VCUG exams [27]. Nevertheless, the radiation
during ﬂuoroscopy is focused on the pelvis while with a
DMSA study, it is diﬀused throughout the body with con-
centration in the kidneys. Sequential exams for surveillance
would increase this exposure. Additional limitations to the
DMSA scan include the need for intravenous access and se-
dation, lack of availability at all centers, inconsistent inter-
pretation of the exam, and the longer duration of the test
(1-2 hours) as compared with VCUG. On the other hand,
the VCUG requires urethral catheterization which can many
times be a focus of discomfort and anxiety for both the
child and parents. In addition, a signiﬁcant proportion of
children will undergo surveillance for a disease that may
never be clinically signiﬁcant. Thus, the search continues
for the optimal methodology of evaluation as well as for
alternative imaging techniques that can overcome the risks
and inadequacies mentioned (Table 1).
3.3. Emerging Technology. As the diagnostic paradigm for
FUTI is evolving, so is the technology available to practition-
ers. The bottom-up versus top-down debate may be altered
signiﬁcantly by the radiographic options on the horizon as
they change diagnostic capabilities and the understanding of
diseaseprocesses.Magneticresonanceurography(MRU)can
providebothanatomicandfunctionaldatainonestudy.Due
to the improved spatial and contrast resolution, congenital
renal dysplasia can be diﬀerentiated from acquired renal
damage on MRU [28]. Chang et al. [29] showed a direct re-
lationship between the renal parenchymal damage and vol-
u m ed e t e c t e db yM R Ua n dV U Rg r a d e .I nar e t r o s p e c t i v e
review of 114 patients with reﬂux, and 21 nonreﬂuxing con-
trols, MRU was able to detect a renal size discrepancy be-
tween the two groups. This size discrepancy persisted in
the comparison of contralateral nonreﬂuxing kidneys with
nonreﬂuxing controls and occurred in the absence of focal
scarring (P<0.0001). This data supports the notion that
patients with VUR can have abnormal embryological devel-
opment or hypoplasia before birth and the ﬁrst insult of
a UTI. Alternatively, the contralateral nonreﬂuxing kidney
may be impacted by bilateral pyelonephritis initiated by
the reﬂuxing kidney. The etiology is still unclear, but the
association between VUR and APN could be characterized
more completely if MRU assessment is included in future
studies.
Anothermagneticresonanceimagingtechniquehasbeen
developed to perform interactive voiding cystourethrogra-
phy (iMRVC), which involves using a pulse sequence and
rapid switching between views to permit prolonged dynamic
imaging of the urinary tract [30]. A feasibility study in un-
sedated infants was performed on 12 patients with a ﬁrst
UTI or abnormalities on early postnatal US [30]. VUR was
identiﬁed in 5 children using iMRVC versus 3 using conven-
tional VCUG (sensitivity 100%, speciﬁcity 83% for iMRVC).
It should be noted that the iMRVC studies followed a single
cycle VCUG study, and subsequent bladder ﬁlling cycles have
been known to increase VUR detection. The iMRVC studies
obtained adequate images of the urethra, and the technique
was reﬁned over the course of the trial such that the imaging
timedroppedfrom60minutesto20minutes,commensurate
with the time required for a VCUG [30].
Both MRU and iMRVC show promise for future use.
They oﬀer exquisite anatomic detail in conjunction with dy-
namic, functional information without the need for radia-
tion. These tests are expensive to administer, require sophis-
ticated processing techniques, and may require sedation in
younger patient populations. Also, intravenous gadolinium
in MRU studies needs to be used with caution in patients
with severe renal impairment due to the risk of a rare but
disabling complication known as nephrogenic systemic fı-
brosis [28]. For research purposes, these modalities can
provide more information about the relationship between
VUR, APN and subsequent renal scarring than currentAdvances in Urology 5
Table 1: Advantages and Disadvantages of Bottom-Up versus Top-Down Methodology.
Advantages Disadvantages Comments
Bottom-Up
VCUG
Widely available with reproducible
techniques and interpretation
Identiﬁes lower urinary tract
correctable anomalies
Requires catheterization
Does not identify all vulnerable kidneys
Exposure to focused ionizing radiation
May overtreat cases that are not
clinically signiﬁcant
VUR will predispose kidneys to
pyelonephritis and scarring but the
relationship is not 1:1
Many cases of VUR spontaneously
resolve
RUS
Noninvasive
No ionizing radiation
Widely available
Fails to alter management as many
abnormalities are now detected in utero
Not a functional study
Gross anatomic assessment to
complement VCUG
Top-Down
DMSA
Identiﬁes kidneys vulnerable to injury
Avoids VCUG (and catheterization)
in a subset of patients
Acute phase scans have high
sensitivity and speciﬁcity for clinically
signiﬁcant VUR and recurrent UTI
Heterogeneity in availability, quality,
and interpretation
Requires intravenous access and long
appointment times
Requires sedation in young children
Misses cases of VUR
If only a late-phase scan is performed,
it may miss patients at risk for
recurrent FUTI
Exposure to diﬀuse ionizing radiation
Early scans may show parenchymal
inﬂammation but only 40% may
progress to scarring
If only late phase scans are
performed, cases of repeat FUTI
will be missed
methodologies. However, these tests do not yet shed light
on the optimal approach to a patient with FUTI. In terms of
clinical practice, the demand for this imaging modality may
outpace the research to support it in this era characterized by
the rapid adoption of new technology.
Tocomefullcircle,theultrasoundmodalitymaybeexpe-
riencing a resurgence at certain centers. Voiding urosonog-
raphy (VUS) has been reﬁned over the last ten years with
the addition of harmonic imaging and second-generation
contrast agents to improve accuracy. A recent comparison of
VUS with VCUG studied 183 children (366RU) with UTI,
uppertractdilation,orpreviouslydiagnosedVUR[31].VUR
was detected in 140RU based on the presence of contrast
material in the ureter or pelvicalyceal system during the
exam; however, VCUG only picked up 14 cases whereas 37
caseswereidentiﬁedwithVUS.Thismaybetheresultofcon-
tinuous imaging using sonography versus intermittent ﬂu-
oroscopy. The prevailing criticism of this technique is that
the urethra cannot be properly visualized. However, Duran
et al. [32] showed that recent technological advances have
enabled diagnosis of posterior urethral valves and diverticula
of the prostatic utricle and the anterior urethra in boys. The
bladderneckandurethrawerefelttobeadequatelyvisualized
in 150 patients included in the study. This is consistent with
prior reports using this technique [33]. Like iMRVC, this
exam still requires catheterization. Unlike iMRVC and MRU,
VUS is less costly and may be more accessible to the general
population. However, the techniques are still operator-de-
pendent and require highly skilled sonographers.
3.4. Other Considerations. Risk factors for scarring have
traditionally included increasing grade of VUR, increasing
frequency of UTI, and presence of bladder and bowel
dysfunction, otherwise known as dysfunctional elimination
[9]. The irony of the top-down approach is that it brings
renewed focus to this type lower urinary tract dysfunction.
Children with APN and no evidence of VUR are often found
to have dysfunctional elimination (DE) [24]. An aggressive,
detailed assessment and treatment of bladder and bowel
dysfunction may identify ways to decrease recurrent UTI
[9, 34]. High bladder capacity and increased residual urine
are used as markers of bladder dysfunction. These variables,
along with renal abnormality on DMSA and recurrent FUTI,
were negative predictors of VUR resolution in a prospective
observational study of 115 children with reﬂux [14]. In the
absence of these three factors, there was a 91% probably
of spontaneous resolution by the age of 3 years in children
with grade III–V VUR. Furthermore, the propensity for scar-
ring is diminished when DE is eﬀectively treated [2]. DE is
a well-established risk factor for recurrent UTI, persistent
VUR,failedmedicalandsurgicalinterventions,andacquired
scarring[22,34].Themeritsofmedicalorsurgicaltreatment
havebeenhotlydebatedintheliterature;however,thecritical
intervention for everyone may be behavioral therapy to
addresstheabnormalbladderandbowelfunction(Figure 1).
Thus, regardless of what type of radiographic evaluation is
done for a child with a FUTI, the more clinically important
interventionmaybetoidentifythosechildrenwithFUTIthat
have dysfunctional elimination and treat it.
Whatmaybemissingfromallofthediscussionregarding
the best type of radiographic evaluation to address children
with FUTIs that are at-risk for renal scarring is the fact that
FUTI (independent of scarring) remains a source of con-
siderable illness and morbidity. Hospitalizations for children
with FUTI cost an estimated $180 million per year in the
United States [24]. Although the surgical correction of VUR6 Advances in Urology
has not been shown to reduce the incidence of infections
or scarring, it is more eﬀective than prophylactic antibiotics
in preventing episodes of febrile infection [35]. The timing
and duration of prophylactic antibiotics in the setting of
FUTI have been controversial, but evidence is accumulating
in favor of their use. The Swedish Reﬂux Trial showed that
female patients on prophylaxis may continue to have FUTI
but are less likely to have new renal scars [23]. A formal Co-
chrane Database review published in 2011 considered all
randomized controlled trials (RCT) and quasi-RCTs that
assessed antibiotic prophylaxis versus placebo or no treat-
ment to prevent recurrence of UTI in children [36]. The
authorsconcludedthatasmallbutconsistentbeneﬁtexistsin
favor of low-dose antibiotic prophylaxis for reducing repeat
infections.
Recent evidence suggests that it is not the severity of
illness that puts kidneys at risk for deterioration but rather
a delay in appropriate therapy [4, 12]. According to both
clinical evidence and basic science research using mature
sows, there is no age limit to developing renal scarring, con-
trary to previous theories [4, 5, 37]. Thus, prompt treatment
of infections remains relevant as long as reﬂux persists. The
purpose of identifying reﬂux or scarring in this cohort is
twofold: ﬁrst, to maintain a heightened awareness that these
patients in particular require timely diagnosis and man-
agement of a febrile illness; second, to institute behavioral
strategies for more eﬀective bladder and bowel elimination.
These basic interventions are less likely to be recommended
if the patient is never referred to a specialist for formal evalu-
ation. To be sure, each imaging technique has its ﬂaws, but
until properly controlled studies are available to guide our
diagnostic eﬀorts, the status quo should be maintained not
abandoned.
To add to the confusion, guidelines from the National
Institute for Health and Clinical Excellence (NICE) in the
United Kingdom suggest that routine imaging for VUR fol-
lowing a typical, uncomplicated UTI is not required [38].
Infants with atypical UTI (deﬁned by severity of illness, poor
response to antibiotics, or a non-E. coli infection) or a
recurrent UTI are the only ones recommended to undergo a
limitedworkup.Thistaperedapproachrepresentsadramatic
deviation from previous standards and reﬂects the opinion
that congenital dysplasia may represent a benign etiology
[37, 38]. In addition, the high spontaneous resolution rates
for some forms of uncomplicated VUR are often cited in
favor of a more limited approach [14]. Also, there has been
renewed emphasis lately on reducing ionizing radiation in
the pediatric population, which argues against an aggressive
or indiscriminate workup of FUTI [39] .H o w e v e r ,ar e c e n t
meta-analysisshowednoreductionintheproportionofchil-
dren with reﬂux nephropathy progressing to ESRD despite
ourcurrentinterventionstrategies[28,40].Thatstatisticwill
not improve with the emerging trend to reduce the evalua-
tion of patients with FUTI. Certainly it would be better to
focus our eﬀorts on patients that are most at-risk for renal
deterioration, but that population has not been satisfactorily
deﬁned at this time.
Although renal parenchymal injury is the most severe
long-term sequela of FUTIs, the morbidity and costs of
recurrent urinary tract infections (especially febrile UTI)
should not be underestimated. Thus, the potential for renal
scarring is one target to identify, but the prevention of FUTI
must be included in the decision-tree algorithm. As we have
seen with the NICE guidelines, some nonurologic forums
have abandoned all consideration of top-down or bottom-
up methodologies; they are beginning to adopt “none of the
above” strategies instead. While the evidence is clearly not
in favor of one approach over the other, the outcomes are
potentially damaging enough to warrant some radiographic
investigation, surveillance, and management by a specialist.
Although the diagnosis of reﬂux or scarring carries an un-
known long-term predictive value, it heightens awareness
among practitioners and the family such that the child is
properly monitored and treated for further febrile events.
4. Conclusions
Currently,theonlynoncontroversialstatementonecanmake
about the radiographic evaluation of children with FUTIs
to identify clinically signiﬁcant vesicoureteral reﬂux is that
it demonstrates the need for solid evidence-based medicine.
A review of the current literature is overwhelming and often
conﬂicting due to diﬀerences in deﬁnitions and criteria for
outcomes. There is controversy in the timing and methods of
diagnosis as well as management. Few well-designed, appro-
priatelypoweredrandomizedstudieshavebeenpublishedon
this subject. Thus, we have traditionally employed a homog-
enous overtreatment strategy in order to avoid undertreating
patients with FUTIs. The only consistently emerging theme
in this debate is the need for individualized therapy rather
than a blanket recommendation regarding the workup and
treatment for this condition.
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